RefleXion is highlighting clinical results from a study conducted on its X1 platform by City of Hope at the Society of Nuclear Medicine and Medical Imaging (SNMMI) meeting in Chicago.
The study evaluated the use of the company's Scintix biology-guided radiotherapy with a prostate-specific PET radiotracer F-18 DCFPyL (Pylarify, Lantheus Medical Imaging) for controlling external-beam radiotherapy delivery to prostate cancer tumor targets, RefleXion said.
Scintix was cleared by the U.S. Food and Drug Administration in February, according to the firm.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
